Clinical trial NCT03343847: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.
Official title: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Lymphomas
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Chemotherapy-induced Thrombocytopenia
Lead sponsor: Amgen
Sponsor class: INDUSTRY
First posted: 2017-11-17
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of lymphomas measured by the ability to administer on-time, full-dose chemotherapy.

Detailed description: This is a phase 3, randomized, placebo-controlled, multicenter, international study for the treatment of CIT in adult subjects receiving chemotherapy for the treatment of lymphomas, defined by 2 platelet counts \< 30 x 10\^9/L at least 7 days apart. The study will consist of a screening period of up to 4 weeks, a 16-week treatment period, an end-of-treatment (EOT) visit, and long-term follow-up.

Eligibility criteria: Inclusion Criteria:

* 101 Subject has provided informed consent/assent prior to initiation of any study-specific activities/procedures or subject's legally acceptable representative has provided informed consent prior to any study-specific activities/procedures being initiated when the subject has any kind of condition that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent.
* 102 Males or females ≥ 18 years of age at signing of the informed consent.
* 103 Documented active lymphoma.
* 104 Receiving cancer treatment with 14-, 21-, or 28-day cycles, using medication such as alkylating agents, anthracyclines, carboplatin, cisplatin, nucleoside analogs, or any other chemotherapy agents with thrombocytopenia as a warning or adverse reaction.
* 105 Subjects must have 2 platelet counts \< 30 x 109/L at least 7 days apart as a result of the chemotherapy administered in the cycle immediately preceding study entry, and no platelet count ≥ 50 x 109/L during 3-week period prior to enrollment despite dose delay or dose modification of chemotherapy regimen. The first platelet count \< 30 x 109/L may be collected from local lab platelet count and must be confirmed within the 28-day screening period.
* 106 Subjects must not have received chemotherapy within 14 days prior to first dose of investigational product.
* 107 Subjects must have at least 4 additional planned cycles of chemotherapy at study enrollment.
* 108 Subjects must be able to receive the same chemotherapy regimen (when possible, same schedule and same agents) for at least 2 additional cycles per investigator judgement.
* 109 Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria:

* 201 Acute lymphoblastic leukemia.
* 202 Acute myeloid leukemia.
* 203 Any myeloid malignancy.
* 204 Myelodysplastic syndrome.
* 205 Myeloproliferative disease.
* 206 Multiple myeloma.
* 207 Within 4 months prior to enrollment, any history of active congestive heart failure (New York Heart Association \[NYHA\] class III to IV), symptomatic ischemia, uncontrolled arrhythmias, clinically significant electrocardiogram (ECG) abnormalities, screening ECG with corrected QT (QTc) interval of \> 470 msec, pericardial disease, or myocardial infarction.
* 208 New or uncontrolled venous thromboembolism or thrombotic events within 3 months prior to screening.
* 209 Known human immunodeficiency virus infection, hepatitis C infection, or hepatitis B infection (subjects with hepatitis B surface antigen or core antibody receiving and responding to antiviral therapy directed at hepatitis B are allowed).
* 210 Secondary malignancy within the past 5 years except: Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. Adequately treated cervical carcinoma in situ without evidence of disease. Adequately treated breast ductal carcinoma in situ without evidence of disease. Prostatic intraepithelial neoplasia without evidence of prostate cáncer. Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ.

Malignancy treated with curative intent and with no known active disease present for ≥ 3 years before enrollment and felt to be at low risk for recurrence by the treating physician (excluding malignancies listed in exclusion criteria 201 to 206).

* 211 Previous use of romiplostim, pegylated recombinant human megakaryocyte growth and development factor, eltrombopag, recombinant human TPO, any other TPO receptor agonist, or any investigational platelet producing agent.
* 212 Currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
* 213 Anemia (hemoglobin \< 8 g/dL) on the day of initiation of investigational product. Use of red cell transfusions and erythropoietic stimulating agents is permitted as per institutional guidelines.
* 214 Neutropenia (absolute neutrophil count \< 1 x 109/L) on the day of initiation of investigational product. Use granulocyte-colony stimulating factor is permitted as per institutional guidelines.
* 215 Abnormal renal function with serum creatinine ≥ 1.5 times \[X\] the upper limit of normal \[ULN\] OR creatinine clearance ≤ 60 mL/min using Cockcroft-Gault estimated creatinine clearance as assessed by central laboratory during screening.
* 216 Abnormal liver function (TBL \> 3x ULN; alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\] \> 3x ULN for subjects without liver metastases or ≥ 5x ULN for subjects with liver metastases) as assessed by central laboratory during screening.

Primary outcomes:
measure: Chemotherapy dose delay or reduction
timeFrame: 17 weeks
Secondary outcomes:
measure: Platelet recovery
timeFrame: 7 days post transfusion through platelet recovery
measure: Platelet count
timeFrame: 7 days after 3rd dose of IP with no transfusions in preceding 7 days
measure: Depth of the platelet count
timeFrame: 3rd dose of IP through End of treatment, up to 43 months
measure: Subject Incidence of Platelet Transfusion
timeFrame: Through treatment period, up to 17 weeks
measure: Bleeding events
timeFrame: Through treatment period, up to 17 weeks
measure: Adverse Events, Serious Adverse Events, clinically significant lab value changes
timeFrame: Through treatment period, up to 17 weeks
measure: Antibody Formation
timeFrame: throughout treatment period, up to 17 weeks
measure: Vital Status
timeFrame: treatment period through end of study, up to 43 months
measure: Changes in health
timeFrame: treatment period through end of study, up to 43 months
Other outcomes:
measure: Platelet count
timeFrame: treatment period through end of study, up to 43 months
measure: Change in Clinical Outcome Assessment (COA) scores
timeFrame: Through treatment period, up to 17 weeks
measure: Change in Health-Related Quality of Life (HRQoL) score
timeFrame: Through treatment period, up to 17 weeks
measure: Romiplostim concentration
timeFrame: Through treatment period, up to 17 weeks
measure: Change in Clinical Outcomes Assessment (COA) scores
timeFrame: Through treatment period, up to 17 weeks
measure: Change in Clinical Outcomes Assessment (COA) scores
timeFrame: Through treatment period, up to 17 weeks
measure: Change in Health-Related Quality of Life (HRQoL) score
timeFrame: Through treatment period, up to 17 weeks
measure: Change in Health-Related Quality of Life (HRQoL) score
timeFrame: Through treatment period, up to 17 weeks
Locations:
Study officials:
affiliation: Amgen
name: MD
role: STUDY_DIRECTOR
References: